Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer initiates study investigating new glaucoma medicine

Pfizer initiates study investigating new glaucoma medicine

3rd January 2008

NicOx has announced that its partner Pfizer has initiated a phase II clinical study in Japan investigating an experimental new medicine for the treatment of glaucoma.

PF-03187207, which is currently in an ongoing phase II proof-of-concept study in the US, will be the subject of the Japanese dose-ranging trial.

The study will compare the safety and efficacy of the medicine compared to Xalatan (latonprost) in Japanese patients with glaucoma or ocular hypertension.

Xalatan is a proprietary Pfizer product and the leader in worldwide glaucoma sales with $1.5billion (750 million pounds) worth of sales in 2006.
Pfizer and NicOx developed the compound as part of their August 2004 collaboration which aimed to focus on the research of nitric oxide-donating prostaglandin F2-alpha analogs in the treatment of glaucoma.

Maarten Beekman, vice-president of clinical development at NicOx, commented: “We believe the initiation of this separate Japanese study for PF-03187207 highlights Pfizer’s determination to rapidly advance this clinical programme towards coordinated regulatory filing in the world’s major pharmaceutical markets.”

He added that NicOx also looked forward to the results of the ongoing-proof-of-concept phase II study for the compound in the US.

At the end of last month, Pfizer and Source MDx formed a multi-year partnership in which both companies will collaborate to develop and validate transitional molecular medicines.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.